Variable | Case (n = 20,869) | Control (n = 62,607) |
---|---|---|
Duration between index stroke and the development of the case, year | 1.70 ± 1.54 | 1.70 ± 1.54 |
Sex, male | 11,710 (56.11) | 3,5130 (56.11) |
Age at index stroke, years | 72.21 ± 10.84 | 72.18 ± 10.81 |
Comorbidities | Â | Â |
 Hypertension | 18,971 (90.91) | 54,801 (87.53) |
 Atrial fibrillation | 5,507 (26.39) | 12,227 (19.53) |
 Malignancy | 3,158 (15.13) | 5,619 (8.98) |
 Renal disease | 7,436 (35.63) | 18,854 (30.12) |
 Coronary artery disease | 4,137 (19.82) | 10,882 (17.38) |
Non-oral antidiabetic medication | Â | Â |
 Insulin | 5,983 (28.67) | 17,949 (28.67) |
 Glucagon-like peptide-1 agonist | 3 (0.01) | 9 (0.01) |
Oral antidiabetic medication | Â | Â |
 Sulfonylurea | 4,038 (19.35) | 12,114 (19.35) |
 Biguanide | 7,702 (36.91) | 23,106 (36.91) |
 Dipeptidyl peptidase 4 inhibitor | 6,352 (30.44) | 19,056 (30.44) |
 Sodium glucose co-transporter-2 inhibitor | 222 (1.06) | 666 (1.06) |
 Meglitinide | 18 (0.09) | 54 (0.09) |
 Alpha-glucosidase inhibitor | 148 (0.71) | 444 (0.71) |
Cardiovascular medication | Â | Â |
 Antiplatelet | 11,119 (53.28) | 40,125 (64.09) |
 Anticoagulant | 2,306 (11.05) | 6,876 (10.98) |
 Statin | 9,901 (47.44) | 37,640 (60.12) |
Thiazolidinedione treatment | Â | Â |
 no thiazolidinedione | 20,226 (96.92) | 59,823 (95.55) |
 Lobeglitazone | 135 (0.65) | 559 (0.89) |
 Pioglitazone | 508 (2.43) | 2,225 (3.55) |